One hundred and ninety-one sera from horses that recently were exposed to West Nile virus (WNV) by either vaccination or natural infection or that were not vaccinated and remained free of infection were used to evaluate fluorescent microsphere immunoassays (MIAs) incorporating recombinant WNV envelope protein (rE) and recombinant nonstructural proteins (rNS1, rNS3, and rNS5) for detection of equine antibodies to WNV. The rE MIA had a diagnostic sensitivity and specificity, respectively, of 99.3% and 97.4% for detection of WNV antibodies in the serum of horses that were recently vaccinated or naturally infected with WNV, as compared to the plaque reduction neutralization test (PRNT). The positive rE MIA results were assumed to be WNV-specific because of the close agreement between this assay and the PRNT and the fact that unvaccinated control horses included in this study were confirmed to be free of exposure to the related St Louis encephalitis virus. The NS protein-based MIA were all less sensitive than either the rE MIA or PRNT (sensitivity 0-48.0), although the rNS1 MIA distinguished horses vaccinated with the recombinant WNV vaccine from those that were immunized with the inactivated WNV vaccine (P , 0.0001) or naturally infected with WNV (P , 0.0001). The rE MIA would appear to provide a rapid, convenient, inexpensive, and accurate test for the screening of equine sera for the presence of antibodies to WNV.
<!?show "fnote_aff1"$^!"content-markup(./author-grp [1] /aff|./author-grp [1] /dept-list)> West Nile virus (WNV) is the cause of West Nile disease (WND), a re-emerging mosquito-transmitted disease of humans and animals. 4, 7, 14 WNV currently occurs throughout Africa, Asia, the Middle East, and portions of Europe and the Americas. [1] [2] [3] [4] [5] [6] [7] [8] [9] WNV was regarded until recently as an infection of birds of limited public health significance, but recent epidemics of WND among humans and horses in Europe and North America have dramatically altered that perception. 4, 7, 10, 14 Horses have been especially impacted during the current North American WNV epidemic, with attendant high morbidity and mortality. 4, 13, 16, [17] [18] [19] [20] A variety of serological assays can be used for detection of WNV-specific antibodies in horse sera, including hemagglutination inhibition, complement fixation, plaque reduction neutralization test (PRNT), immunoglobulin M capture enzyme-linked immunosorbent assay (MAC-ELISA) and immunoglobulin G (IgG) ELISA. 4, 6, 15 Of these, only the PRNT is specific for WNV because antibodies to related flaviviruses such as St. Louis encephalitis virus (SLEV) potentially can cross-react in the other assays. The MAC-ELISA is used to confirm recent WNV infection, 15 whereas the IgG ELISA is useful for serosurveillance if potential crossreactions with other flaviviruses are excluded. 4, 6 A recombinant WNV envelope protein (rE)-based fluorescent microsphere immunoassay (MIA) has been recently developed to titrate antibodies induced by flavivirus infections in humans. 22 Additional MIA that incorporate recombinant NS3 and NS5 (rNS3 and rNS5) were also developed to discriminate WNVspecific antibodies in human sera from those against dengue and SLEV, 21 because of the potential cross-reactivity of antibodies directed against the E protein of different flaviviruses.
The objective of this study was to determine the ability of MIAs incorporating rE, recombinant NS1 (rNS1), rNS3, and rNS5 to detect antibodies to WNV in the sera of vaccinated and naturally infected horses. Sera were collected at monthly intervals from a cohort of 191 horses housed at the Center for Equine Health at the University of California that included 36 unvaccinated horses, 87 horses vaccinated with an inactivated WNV vaccine, a,12 and 68 vaccinated with a recombinant canarypox vaccine expressing the E and M proteins of WNV, b,9 as described in Table 1 . WNV appeared for the first time at the Center for Equine Health in the late summer of 2004 as determined by regular screening of mosquitoes trapped at the site by WNV-specific polymerase chain reaction and by serological surveillance of horses (data not shown). Sera collected in April 2005, after annual revaccination with homologous vaccine of the vaccinated horses and before the anticipated beginning of the WNV season in 2005, were evaluated by MIA and PRNT assays.
The 191 equine sera were evaluated for the presence of anti-WNV antibodies by multiplex MIA targeting the E, NS1, NS3, and NS5 proteins of WNV, as previously described. 21, 22 Briefly, approximately 50 mg of each recombinant protein was covalently conjugated to the free carboxyl groups of xMAP Multi-Analyte COOH Microspheres c according to the manufacturer's protocol. Each recombinant protein was coupled to 6.25 3 10 6 microspheres, and the microspheres were counted using a hemocytometer so that equivalent quantities of each distinct bead set were incorporated into the assay. A 96-well 1.2-mm filter plate d was blocked for 2 minutes with 100 ml of phosphate buffered saline (pH 7.4) with 1% bovine serum albumin and 0.02% sodium azide (PBN buffer) and washed once with 190 ml of phosphate buffered saline (pH 7.4) with 0.05% Tween 20 (PBS-T buffer). Wells were kept moist by addition of 20 ml of PBN buffer. Equine sera (50 ml, diluted 1 : 100 in PBN buffer) were added to each well of the filter plate. Approximately 2,500 recombinant antigen-conjugated microspheres per protein were added to each well in 50 ml of PBN buffer. The plate was incubated in the dark on a shaker at 37uC for 30 minutes and then washed 3 times with PBS-T using a vacuum manifold. Affinity purified biotin labeled goat anti-equine IgG e (50 ml of a 1 : 1000 dilution in PBN buffer) was added, and the plate was incubated in the dark on a shaker at 37uC for 30 minutes and then washed 3 times with PBS-T using a vacuum manifold. Streptavidin conjugated with Rphycoerythrin f (50 ml of a 1 : 100 dilution in PBN buffer) was added, and the plate was incubated in the dark on a shaker at 37uC for 30 minutes and then washed twice with PBS-T using a vacuum manifold. The microspheres were then resuspended in 125 ml of PBN per well, and 75 ml of suspension was transferred to a clear polystyrene 96-well plate. c Microspheres flow through a single-pass channel within the Luminex 100 instrument, a and the median fluorescence intensity was quantified for 100 microspheres and recorded for each well.
The same equine sera were also screened for WNV neutralizing antibodies by PRNT at the National Veterinary Services Laboratory, Ames, Iowa. 2, 13 The proportion of MIA-positive horses in the different vaccination groups was compared by chi-square test.
The rE MIA and PRNT gave identical results for 189/ 191 (99.0%) samples, and the area under the receiveroperating characteristic curve for the rE MIA compared with the PRNT was 0.995 (95% confidence interval, 0.972 to 0.999). Similar findings were evident when results were grouped by vaccination status/category (Table 1) . Specifically, all 68 horses that were vaccinated with the recombinant canarypox-vectored WNV vaccine were positive by both PRNT and rE MIA, and 73 of 75 horses that were annually vaccinated with the inactivated WNV vaccine were also serologically positive by both assays. Two horses that were annually vaccinated with the inactivated WNV vaccine were seronegative by both rE MIA and PRNT, as were 7 of 12 horses that received a single inoculation of this vaccine in 2004. All but 7 of the sera collected in April 2005 from the 36 unvaccinated horses were negative by both rE MIA and PRNT. Of these 7 sera, 5 were positive by both assays, whereas sera collected from individual unvaccinated horses in April 2005 were positive by either PRNT or rE MIA but not both. Sera collected from these same 2 horses in subsequent months were strongly positive to WNV by both PRNT and rE MIA (data not shown), indicating that the 2 horses were likely infected with WNV early in the 2005 season (before serum collection in late April). Hence, the estimates of the sensitivity and specificity of the rE MIA (Table 2 ) are likely conservative.
The unvaccinated horses were all seronegative to SLEV by PRNT, 11 confirming that the positive results obtained by WNV MIA were not the result of cross-reaction from prior infection of the horses with SLE virus. Moreover, no evidence of SLEV infection of horses in California was detected in an extensive recent serological survey of horses throughout the state. 11 Thus, the rE MIA is appropriate for serological surveillance of WNV infection of horses, provided that selected positive sera are also positive by WNV PRNT and confirmed to be free of antibodies to related flaviviruses such as SLEV.
The diagnostic sensitivity (99%) and specificity (97%) of the rE MIA relative to the PRNT are excellent for the detection of WNV antibodies in sera from recently infected or vaccinated horses. However, the rE MIA is more convenient and rapid than the PRNT, especially for the screening of large numbers of sera. The MIA can be completed within a few hours as compared to the PRNT, which takes several days, and the MIA does not use live virus and so does not require biocontainment facilities.
The MIA also provides a quantitative assessment of the antibody titer, whereas the PRNT requires laborious serial dilution of serum to determine antibody titers. However, it is to be stressed that only sera from recently vaccinated and infected horses were evaluated, and the longevity of the WNV-specific antibodies detected by rE MIA was not determined. The rNS1-, rNS3-, and rNS5-based MIAs were markedly less sensitive than both the PRNT and rE MIA in detecting prior vaccination or infection of horses with WNV (Table 2) , and they do not have adequate sensitivity for routine diagnostic use. Although the rNS1, rNS3, and rNS5 MIAs are less sensitive than the rE MIA, the rNS1 MIA is still potentially useful for the laboratory diagnosis of WNV infection of horses since this assay was positive in 5 of the 6 horses that were naturally infected with WNV (as determined by PRNT and rE MIA), as well as 65 of 75 horses that were repeatedly vaccinated with the inactivated WNV vaccine and 2 of the 12 horses that received only a single immunization with this product. Whereas the horses that were vaccinated with the inactivated WNV vaccine typically responded to NS1, those receiving the recombinant canarypox vectored vaccine did not, because this construct contains no WNV NS proteins. The one horse that was vaccinated with the recombinant vaccine that also was positive by rNS1 MIA might represent a false positive result or, more likely, this horse was naturally infected with WNV after vaccination. Thus, the rNS1 MIA is potentially useful in distinguishing horses vaccinated with the recombinant vaccine from those that are either naturally infected with WNV (P , 0.0001) or repeatedly immunized with the inactivated WNV vaccine (P , 0.0001). In summary, the MIA would appear to provide a sensitive, rapid, and convenient assay for the detection of WNV antibodies in equine sera that is especially suitable for large-scale epidemiological studies. { Confidence intervals (CI) calculated by exact binomial methods.
